Impact of preoperative mitral regurgitation on left ventricular assist device patients: propensity score-matched analysis of the EUROMACS dataset.


Journal

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
ISSN: 1873-734X
Titre abrégé: Eur J Cardiothorac Surg
Pays: Germany
ID NLM: 8804069

Informations de publication

Date de publication:
03 02 2023
Historique:
received: 17 07 2022
revised: 02 11 2022
accepted: 11 01 2023
pubmed: 14 1 2023
medline: 10 2 2023
entrez: 13 1 2023
Statut: ppublish

Résumé

Mitral regurgitation (MR) is frequently observed in patients undergoing left ventricular assist device implantation. We investigated the impact of preoperative MR on left ventricular assist device patients. A retrospective propensity score-matched analysis of adult patients enrolled in the EUROMACS registry between 1 January 2011 and 30 November 2021 was performed. Patients were divided into 2 groups according to the grade of preoperative MR: none-to-mild (MR 0-II) or moderate-to-severe (MR III-IV). Following 1:1 propensity score matching, each group consisted of 914 patients. Incidence of postoperative temporary right ventricular support, reoperation for bleeding and dialysis was similar. MR III-IV demonstrated shorter median intensive care unit stay [14 days (6; 27.8) vs 10 days (5; 22), P = 0.004] and ventilation time [72 h (22, 320) vs 31 h (18, 150), P < 0.001]. Mortality was lower for MR III-IV patients [subdistribution hazard ratio: 0.66, 95% confidence interval (CI): 0.59-0.73, P < 0.001]. The 1-year survival was 68.1% (95% CI: 65.1-71.3%) in MR 0-II and 75% (95% CI: 72.1-78%) in MR III-IV. A lower incidence of total complications [odds ratio (OR): 0.93 (0.89-0.98), P = 0.003] and trend towards a lower risk of neurological dysfunction (subdistribution hazard ratio: 0.79; 95% CI: 0.61-1.01, P = 0.063) and sustained ventricular tachycardia [OR: 0.93 (0.54-1.03), P = 0.074] were demonstrated for MR III-IV. The risk of fatal stroke and pump thrombosis was similar. Moderate-to-severe MR in patients undergoing left ventricular assist device implantation is associated with better mid-term survival and lower incidence of total major adverse events and complications. The incidence of severe postoperative complications including fatal stroke and device thrombosis was similar.

Identifiants

pubmed: 36637204
pii: 6986977
doi: 10.1093/ejcts/ezad013
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : EACTS

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Auteurs

Antonio Loforte (A)

Department of Cardiac Surgery, S. Orsola University Hospital, IRCCS Bologna, Bologna, Italy.

Gaik Nersesian (G)

Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany.
DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany.

Daniel Lewin (D)

Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany.

Pia Lanmueller (P)

Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany.
DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany.

Gregorio Gliozzi (G)

Department of Cardiac Surgery, S. Orsola University Hospital, IRCCS Bologna, Bologna, Italy.

Julia Stein (J)

Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany.

Giulio Giovanni Cavalli (GG)

Department of Cardiac Surgery, S. Orsola University Hospital, IRCCS Bologna, Bologna, Italy.

Felix Schoenrath (F)

Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany.
DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany.
Department of Cardiovascular Surgery, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Ivan Netuka (I)

Department of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.

Daniel Zimpfer (D)

Department of Cardiothoracic Surgery, Medical University of Vienna, Vienna, Austria.

Theo M M H de By (TMMH)

EUROMACS Registry, EACTS, Windsor, UK.

Jan Gummert (J)

Department of Thoracic, Cardiac and Vascular Surgery (Heart and Diabetes Centre), North Rhine Westphalia, Bad Oeynhausen, Germany.

Volkmar Falk (V)

Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany.
DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany.
Department of Cardiovascular Surgery, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Department of Health Sciences and Technology, ETH Zurich, Zürich, Switzerland.

Bart Meyns (B)

Department of Cardiac Surgery, University Hospital Leuven, Leuven, Belgium.

Gloria Faerber (G)

Department of Cardiothoracic Surgery, Jena University Hospital, Friedrich-Schiller-University Jena, Jena, Germany.

Davide Pacini (D)

Department of Cardiac Surgery, S. Orsola University Hospital, IRCCS Bologna, Bologna, Italy.

Evgenij Potapov (E)

Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany.
DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH